Immix Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
Immix Biopharma has a total shareholder equity of $17.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $25.1M and $7.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$19.69m |
| Equity | US$17.55m |
| Total liabilities | US$7.59m |
| Total assets | US$25.14m |
Recent financial health updates
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?
Nov 11
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Aug 12Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13Recent updates
Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Deliver On Growth Plans?
Nov 11Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Aug 12Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
Nov 28Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?
Jul 12We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate
Mar 29Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans
Sep 13We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely
May 21Financial Position Analysis
Short Term Liabilities: IMMX's short term assets ($22.8M) exceed its short term liabilities ($6.6M).
Long Term Liabilities: IMMX's short term assets ($22.8M) exceed its long term liabilities ($1.0M).
Debt to Equity History and Analysis
Debt Level: IMMX is debt free.
Reducing Debt: IMMX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMMX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMMX has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 62.8% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:32 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Immix Biopharma, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Robert Burns | H.C. Wainwright & Co. |
| Jonathan Aschoff | Roth MKM |